Maria V. Sergeeva

1.8k citations

62 papers · 957 indexed · h-index 17

Infectious Diseases top 5%
- SARS-CoV-2 and COVID-19 Research 7
- Viral gastroenteritis research and epidemiology 6
- HIV/AIDS drug development and treatment 5
Molecular Biology
- RNA and protein synthesis mechanisms 6
- vaccines and immunoinformatics approaches 5
Biotechnology top 10%
Hepatology
Epidemiology
- Influenza Virus Research Studies 31
- Respiratory viral infections research 13
Immunology
- interferon and immune responses 7

Co-authors: Yuri L. Khmelnitsky Vadim V. Mozhaev Jonathan S. Dordick Karel Martínek A. B. BelovaPing WangVikram Paradkar Joseph O. Rich
Cited by: Infectious Diseases Molecular Biology Biotechnology
Journals: Nature Communications (1 paper)SHILAP Revista de lepidopterología (6 papers)Nature Biotechnology (1 paper)
Partner nations: Russia United States Germany

In The Last Decade

Maria V. Sergeeva

57 papers receiving 906 citations

Peers

Countries citing papers authored by Maria V. Sergeeva

Since Specialization

Citations

This map shows the geographic impact of Maria V. Sergeeva's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maria V. Sergeeva with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maria V. Sergeeva more than expected).

Fields of papers citing papers by Maria V. Sergeeva

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maria V. Sergeeva. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maria V. Sergeeva. The network helps show where Maria V. Sergeeva may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Maria V. Sergeeva, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Maria V. Sergeeva Line = papers co-authored together Maria V. Sergeeva links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	A Knockout of the IFITM3 Gene Increases the Sensitivity of WI-38 VA13 Cells to the Influenza A Virus International Journal of Molecular Sciences ·Natalya Eshchenko,Maria V. Sergeeva,Evgenii Zhuravlev,Kira Kudria,Е. П. Гончарова,Andrey B. Komissarov,Г. А. Степанов	2024	1
2	Mucosal Immunization with an Influenza Vector Carrying SARS-CoV-2 N Protein Protects Naïve Mice and Prevents Disease Enhancement in Seropositive Th2-Prone Mice Vaccines ·Maria V. Sergeeva,Kirill Vasilev,Ekaterina Romanovskaya-Romanko,Nikita Yolshin,Anastasia Pulkina,Daria Shamakova,Anna-Polina Shurygina,Arman Muzhikyan,Dmitry Lioznov,Marina Stukova	2024	0
3	Assessment of the humoral immune response in children after immunization with different types of inactivated influenza vaccines in the 2019-2020 season SHILAP Revista de lepidopterología ·Zh. V. Buzitskaya,А. Б. Попов,Ekaterina Romanovskaya-Romanko,Maria V. Sergeeva,E. A. Varyushina,М. К. Ерофеева,Marina Stukova,Dmitry Lioznov	2023	1
4	IgGκ Signal Peptide Enhances the Efficacy of an Influenza Vector Vaccine against Respiratory Syncytial Virus Infection in Mice International Journal of Molecular Sciences ·Anastasia Pulkina,Kirill Vasilyev,Arman Muzhikyan,Maria V. Sergeeva,Ekaterina Romanovskaya-Romanko,Anna-Polina Shurygina,Marina A. Shuklina,Andrey V. Vasin,Marina Stukova,Andrej Egorov	2023	7
5	Structural and Immunoreactivity Properties of the SARS-CoV-2 Spike Protein upon the Development of an Inactivated Vaccine Viruses ·Larisa V. Kordyukova,Andrey Moiseenko,Marina V. Serebryakova,Marina A. Shuklina,Maria V. Sergeeva,Dmitry Lioznov,Andrei V. Shanko	2023	7
6	Rapid Assessment of Neutralizing Antibodies Using Influenza Viruses with a Luciferase Reporter Applied Biochemistry and Microbiology ·Maria V. Sergeeva,Anastasia Pulkina,Ekaterina Romanovskaya-Romanko,Aigul Mustafaeva,Andrej Egorov,Marina Stukova	2022	1
7	Enhancement of the Local CD8+ T-Cellular Immune Response to Mycobacterium tuberculosis in BCG-Primed Mice after Intranasal Administration of Influenza Vector Vaccine Carrying TB10.4 and HspX Antigens Vaccines ·Kirill Vasilyev,Anna-Polina Shurygina,Natalia Zabolotnykh,Maria V. Sergeeva,Ekaterina Romanovskaya-Romanko,Anastasia Pulkina,Janna Buzitskaya,Marine Dogonadze,Tatiana Vinogradova,Marina Stukova	2021	14
8	Mucosal Influenza Vector Vaccine Carrying TB10.4 and HspX Antigens Provides Protection against Mycobacterium tuberculosis in Mice and Guinea Pigs Vaccines ·Maria V. Sergeeva,Ekaterina Romanovskaya-Romanko,Natalia Zabolotnyh,Anastasia Pulkina,Kirill Vasilyev,Anna Polina Sergeevna Shurigina,Janna Buzitskaya,Yana Zabrodskaya,Artem Fadeev,Andrey V. Vasin,Tatiana Vinogradova,Marina Stukova	2021	18
9	Genomic epidemiology of the early stages of the SARS-CoV-2 outbreak in Russia Nature Communications ·Andrey B. Komissarov,Ksenia R. Safina,Sofya K. Garushyants,Artem Fadeev,Maria V. Sergeeva,A. A. Ivanova,Daria Danilenko,Dmitry Lioznov,Olga V. Shneider,Nikita Shvyrev,Vadim Spirin,Dmitry Glyzin,Vladimir Shchur,Georgii A. Bazykin	2021	40
10	CRISPR-Cas9 mediated knockout of AnxA6 gene enhances influenza A virus replication in low-permissive HEK293FT cell line Gene ·Andrey B. Komissarov,Maria V. Sergeeva,Evgenii Zhuravlev,S. P. Medvedev,Anastasia A. Malakhova,Evgeniya Andreeva,Anna-Polina Shurygina,Andrey Gorshkov,M Ia Timofeeva,Evgenia Balakhonova,Grudinin Mp,Suren M. Zakian,Vladimir A. Richter,Г. А. Степанов	2021	6
11	Old dog, new tricks: Influenza A virus NS1 and in vitro fibrillogenesis Biochimie ·Aram A. Shaldzhyan,Yana Zabrodskaya,Irina Baranovskaya,Maria V. Sergeeva,Andrey Gorshkov,I.I. Savin,Sergey M. Shishlyannikov,Edward S. Ramsay,А. В. Протасов,A.P. Kukhareva,Egorov Vv	2021	6
12	RNA-Seq transcriptome data of human cells infected with influenza A/Puerto Rico/8/1934 (H1N1) virus SHILAP Revista de lepidopterología ·Evgenii Zhuravlev,Maria V. Sergeeva,Sergey Malanin,Р. Н. Амирханов,Dmitriy Semenov,Tatiana V. Grigoryeva,Andrey B. Komissarov,Г. А. Степанов	2020	5
13	Obtaining and Characteristics of Monoclonal Antibody Panel Specific to NS1 Protein of A Flu Virus Biotekhnologiya ·V. Z. Krivitskaya,Е. В. Сорокин,Т. Р. Царева,Maria V. Sergeeva,Renata A. Kadyrova,Ekaterina Romanovskaya-Romanko,Aram A. Shaldzhyan,С. Б. Петров,Н. И. Коновалова,P. A. Petrova	2017	2
14	Egg‐ or cell culture‐derived hemagglutinin mutations impair virus stability and antigen content of inactivated influenza vaccines Biotechnology Journal ·Sabine Nakowitsch,Andrea Waltenberger,Nina Wressnigg,Nicole Ferstl,Andrea Triendl,Bettina Kiefmann,Emanuele Montomoli,Giulia Lapini,Maria V. Sergeeva,Thomas Muster,Julia Romanova	2013	19
15	Mass spectrometry and biochemical analysis of RNA polymerase II: targeting by protein phosphatase-1 Molecular and Cellular Biochemistry ·Marina Jerebtsova,С. А. Клотченко,Т. О. Артамонова,Tatiana Ammosova,Kareem Washington,Egorov Vv,Aram A. Shaldzhyan,Maria V. Sergeeva,Evgeny Zatulovskiy,Olga A. Temkina,Mikhail G. Petukhov,Andrey V. Vasin,М. А. Ходорковский,Yuri N. Orlov,Sergeï Nekhai	2010	18
16	Hexahydro-pyrrolo- and hexahydro-1H-pyrido[1,2-b]pyridazin-2-ones as potent inhibitors of HCV NS5B polymerase Bioorganic & Medicinal Chemistry Letters ·Frank Ruebsam,Zhongxiang Sun,Benjamin K. Ayida,Stephen E. Webber,Yuefen Zhou,Qiang Zhao,Charles R. Kissinger,Richard E. Showalter,Amit Shah,Mei Tsan,Rupal Patel,Laurie A. LeBrun,Ruhi Kamran,Maria V. Sergeeva,Darian M. Bartkowski,Thomas G. Nolan,Daniel A. Norris,Leo Kirkovsky	2008	10
17	Novel HCV NS5B polymerase inhibitors derived from 4-(1′,1′-dioxo-1′,4′-dihydro-1′λ6-benzo[1′,2′,4′]thiadiazin-3′-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 5: Exploration of pyridazinones containing 6-amino-substituents Bioorganic & Medicinal Chemistry Letters ·Peter S. Dragovich,Julie Blazel,David A. Ellis,Qing Han,Ruhi Kamran,Charles R. Kissinger,Laurie A. LeBrun,Lian‐Sheng Li,Douglas E. Murphy,Michael Noble,Rupal Patel,Frank Ruebsam,Maria V. Sergeeva,Amit Shah,Richard E. Showalter,Chinh Van Tran,Mei Tsan,Stephen E. Webber,Leo Kirkovsky,Yuefen Zhou	2008	20
18	Kinetic properties of human thymidylate synthase, an anticancer drug target Biochemical and Biophysical Research Communications ·Oksana A. Sergeeva,H.Godrej Khambatta,Brian E. Cathers,Maria V. Sergeeva	2003	11
19	Enzyme-catalyzed therapeutic agent (ECTA) design: activation of the antitumor ECTA compound NB1011 by thymidylate synthase11Abbreviations: BVdU, (E)-5-(2-bromovinyl)-2′-deoxyuridine; BVdUMP, (E)-5-(2-bromovinyl)-2′-deoxyuridine 5′-monophosphate; NB1011, (E)-5-(2-bromovinyl)-2′-deoxy-5′-uridyl phenyl l-methoxyalaninylphosphoramidate; COSY, correlated spectroscopy; DCI, direct current ionization; DMF, N,N-dimethylformamide; dUMP, 2′-deoxyuridine 5′-monophosphate; ECTA, enzyme-catalyzed therapeutic agent; 5-FU, 5-fluorouracil; 5-FdUMP, 5-fluoro-2′-deoxyuridine 5′-monophosphate; RFU, relative fluorescence units; THF, N5,N10-methylene tetrahydrofolate; TBDMS, tert-butyldimethylsilyl; and TS, thymidylate synthase (EC 2.1.1.45). Biochemical Pharmacology ·David Bruce Lackey,Michael P. Groziak,Maria V. Sergeeva,Malgorzata Beryt,Christopher R. Boyer,Robert M. Stroud,Peter H. Sayre,John W. Park,Patrick Johnston,Dennis J. Slamon,H. Michael Shepard,Mark D. Pegram	2001	29
20	The evolution of biotransformation technologies Current Opinion in Microbiology ·Jonathan S. Dordick,Yuri L. Khmelnitsky,Maria V. Sergeeva	1998	30

About Maria V. Sergeeva

Maria V. Sergeeva is a scholar working on Epidemiology, Infectious Diseases and Immunology, having authored 62 papers that have together received 957 indexed citations. Recurring topics across this work include Influenza Virus Research Studies (31 papers), Respiratory viral infections research (13 papers), interferon and immune responses (7 papers), SARS-CoV-2 and COVID-19 Research (7 papers), RNA and protein synthesis mechanisms (6 papers), Viral gastroenteritis research and epidemiology (6 papers), vaccines and immunoinformatics approaches (5 papers) and HIV/AIDS drug development and treatment (5 papers). The work is most often cited by research in Infectious Diseases (250 citations), Molecular Biology (507 citations) and Biotechnology (55 citations). Maria V. Sergeeva has collaborated with scholars based in Russia, United States and Germany. Frequent co-authors include Yuri L. Khmelnitsky, Vadim V. Mozhaev, Jonathan S. Dordick, Karel Martínek, A. B. Belova, Ping Wang, Vikram Paradkar, Joseph O. Rich, Marina Stukova and Andrey B. Komissarov. Their work appears in journals such as Nature Communications, SHILAP Revista de lepidopterología and Nature Biotechnology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact